Pub. Date : 2012 Feb
PMID : 21838784
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. | montelukast | cytochrome P450 family 2 subfamily C member 8 | Homo sapiens |
| 2 | Our aim was to study the effects of selective CYP2C8 and CYP3A4 inhibitors on the pharmacokinetics of montelukast. | montelukast | cytochrome P450 family 2 subfamily C member 8 | Homo sapiens |
| 3 | Plasma concentrations of montelukast, gemfibrozil, itraconazole and their metabolites were measured up to 72 h. RESULTS: The CYP2C8 inhibitor gemfibrozil increased the AUC(0, ) of montelukast 4.3-fold and its t(1/2) 2.1-fold (P < 0.001). | montelukast | cytochrome P450 family 2 subfamily C member 8 | Homo sapiens |
| 4 | Plasma concentrations of montelukast, gemfibrozil, itraconazole and their metabolites were measured up to 72 h. RESULTS: The CYP2C8 inhibitor gemfibrozil increased the AUC(0, ) of montelukast 4.3-fold and its t(1/2) 2.1-fold (P < 0.001). | montelukast | cytochrome P450 family 2 subfamily C member 8 | Homo sapiens |
| 5 | CONCLUSIONS: CYP2C8 is the dominant enzyme in the biotransformation of montelukast in humans, accounting for about 80% of its metabolism. | montelukast | cytochrome P450 family 2 subfamily C member 8 | Homo sapiens |
| 6 | Montelukast may serve as a safe and useful CYP2C8 probe drug. | montelukast | cytochrome P450 family 2 subfamily C member 8 | Homo sapiens |